echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Transl Lung Cancer Res: The Huaxi team showed that the use of video-assisted thoracoscopy (VATS) and thoracotomy (OT) for lobectomy and PAA in patients with lung cancer are comparable

    Transl Lung Cancer Res: The Huaxi team showed that the use of video-assisted thoracoscopy (VATS) and thoracotomy (OT) for lobectomy and PAA in patients with lung cancer are comparable

    • Last Update: 2022-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pulmonary artery angioplasty (PAA) is an important surgical procedure that completes radical resection in the case of pulmonary artery involvement to maximize the preservation of lung tissue function
    .


    In this study, the purpose of this study was to evaluate the short- and long-term outcomes of lobectomy and PAA using video-assisted thoracoscopy (VATS) versus thoracotomy (OT) in lung cancer surgery


    Pulmonary artery angioplasty (PAA) is an important surgical procedure that completes radical resection in the case of pulmonary artery involvement to maximize the preservation of lung tissue function


    We retrospectively studied 214 patients who received PAA between November 2005 and October 2016
    .


    Propensity score matching (PSM) was used to reduce confounding effects


    We retrospectively studied 214 patients who received PAA between November 2005 and October 2016


    The final study included 203 patients (28 in the VATS group and 175 in the OT group)


    There were no differences between the two groups in terms of operation time, blood loss, chest tube drainage time, postoperative hospital stay, surgical margin, postoperative morbidity, mortality, number of N1 and N2 stations, and number of N1 and N2 lymph nodes before and after matching
    .

    There were no differences between the two groups in terms of operation time, blood loss, chest tube drainage time, postoperative hospital stay, surgical margin, postoperative morbidity, mortality, number of N1 and N2 stations, and number of N1 and N2 lymph nodes before and after matching
    .


    With a median follow-up of 43 months (6-158 months), the 5-year overall survival (OS) and recurrence-free survival (RFS) of the entire cohort were 47.
    9% and 42.
    1%, respectively
    .

    With a median follow-up of 43 months (6-158 months), the 5-year overall survival (OS) and recurrence-free survival (RFS) of the entire cohort were 47.
    9% and 42.
    1%, respectively
    .


    With a median follow-up of 43 months (6-158 months), the 5-year overall survival (OS) and recurrence-free survival (RFS) of the entire cohort were 47.


    5-year OS in the VATS and OT groups in the overall cohort [49.


    Differences in OS before PSM treatment

     Differences in OS before PSM treatment

    Differences in treatment OS after PSM

    Differences in treatment OS after PSM

    Likewise, the 5-year RFS rates in the VATS and OT groups were higher in the overall cohort [39.
    1% (95% CI: 23.
    4 65.
    2%) vs.
    42.
    6% (95% CI: 35.
    4 51.
    1%)] and matched cohorts [39.
    1% (95%) CI: 23.
    4 65.
    2%) vs.
    44.
    1% (95% CI: 32.
    1 60.
    5%)]
    .

    Likewise, the 5-year RFS rates in the VATS and OT groups were higher in the overall cohort [39.
    1% (95% CI: 23.
    4 65.
    2%) vs.
    42.
    6% (95% CI: 35.
    4 51.
    1%)] and matched cohorts [39.
    1% (95%) CI: 23.
    4 65.
    2%) vs.
    44.
    1% (95% CI: 32.
    1 60.
    5%)]
    .


    Likewise, the 5-year RFS rates in the VATS and OT groups were higher in the overall cohort [39.


                     Differences in RFS before PSM treatment

     Differences in RFS before PSM treatment

                   Treatment RFS Differences After PSM

                   Treatment RFS Differences After PSM

    N2 lymph node dissection ≥ 11 (hazard ratio 0.
    36; 95% CI: 0.
    14 - 0.
    93, P=0.
    035) was the only factor favorable for OS
    .


    Charlson comorbidity index 2 (hazard ratio, 0.


    N2 lymph node dissection ≥ 11 (hazard ratio 0.


    In conclusion, studies have shown that video-assisted thoracoscopy (VATS) is comparable to thoracotomy (OT) for lobectomy and PAA in the treatment of lung cancer patients
    .
    Studies have shown that video-assisted thoracoscopy (VATS) is comparable to thoracotomy (OT) for lobectomy and PAA in the treatment of lung cancer patients
    .
    Studies have shown that video-assisted thoracoscopy (VATS) is comparable to thoracotomy (OT) for lobectomy and PAA in the treatment of lung cancer patients
    .

    Original source:

    Original source:

    Liu C, Yang Z, Guo C, Zhu Y, Pu Q, Mei J, Ma L, Lin F, Liu L.
    Lobectomy with pulmonary artery angioplasty for lung cancer using video-assisted thoracic surgery versus open thoracotomy: a retrospective propensity matched analysis .
    Transl Lung Cancer Res 2021;10(10):3943-3956.
    doi: 10.
    21037/tlcr-21-607

    Liu C, Yang Z, Guo C, Zhu Y, Pu Q, Mei J, Ma L, Lin F, Liu L.
    Lobectomy with pulmonary artery angioplasty for lung cancer using video-assisted thoracic surgery versus open thoracotomy: a retrospective propensity matched analysis .
    Transl Lung Cancer Res 2021;10(10):3943-3956.
    doi: 10.
    21037/tlcr-21-607 Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.